دورية أكاديمية
أعرض في EDS

Prognostic effect of TCF1+ CD8+ T cell and TOX+ CD8+ T cell infiltration in lung adenocarcinoma.

التفاصيل البيبلوغرافية
العنوان: Prognostic effect of TCF1+ CD8+ T cell and TOX+ CD8+ T cell infiltration in lung adenocarcinoma.
المؤلفون: Wang Y; Department of Radiation Oncology and Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.; Research Unit of Radiation Oncology, Chinese Academy of Medical Sciences, Jinan, China., Ma L; Research Unit of Radiation Oncology, Chinese Academy of Medical Sciences, Jinan, China.; Department of Oncology, Renmin Hospital of Wuhan University, Wuhan, China., Chen Y; Research Unit of Radiation Oncology, Chinese Academy of Medical Sciences, Jinan, China.; Cheeloo College of Medicine, Shandong University, Jinan, China., Yun W; Department of Radiation Oncology and Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.; Research Unit of Radiation Oncology, Chinese Academy of Medical Sciences, Jinan, China., Yu J; Department of Radiation Oncology and Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.; Research Unit of Radiation Oncology, Chinese Academy of Medical Sciences, Jinan, China., Meng X; Department of Radiation Oncology and Shandong Provincial Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.; Research Unit of Radiation Oncology, Chinese Academy of Medical Sciences, Jinan, China.
المصدر: Cancer science [Cancer Sci] 2024 Jul; Vol. 115 (7), pp. 2184-2195. Date of Electronic Publication: 2024 Apr 09.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Wiley Publishing on behalf of the Japanese Cancer Association Country of Publication: England NLM ID: 101168776 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1349-7006 (Electronic) Linking ISSN: 13479032 NLM ISO Abbreviation: Cancer Sci Subsets: MEDLINE
أسماء مطبوعة: Publication: 2005- : Oxford : Wiley Publishing on behalf of the Japanese Cancer Association
Original Publication: Tokyo : Japanese Cancer Association, c2003-
مواضيع طبية MeSH: CD8-Positive T-Lymphocytes*/immunology , CD8-Positive T-Lymphocytes*/metabolism , Adenocarcinoma of Lung*/immunology , Adenocarcinoma of Lung*/pathology , Adenocarcinoma of Lung*/mortality , Lung Neoplasms*/immunology , Lung Neoplasms*/pathology , Lung Neoplasms*/mortality , Hepatocyte Nuclear Factor 1-alpha*/metabolism , Hepatocyte Nuclear Factor 1-alpha*/genetics , Lymphocytes, Tumor-Infiltrating*/immunology , Lymphocytes, Tumor-Infiltrating*/metabolism, Humans ; Female ; Prognosis ; Male ; Middle Aged ; Aged ; Retrospective Studies ; Tumor Microenvironment/immunology ; Disease-Free Survival ; High Mobility Group Proteins/metabolism ; Trans-Activators
مستخلص: Recent studies have highlighted the pivotal roles of T cell transcription factors TCF-1 and TOX in modulating the immune response in cancer, with TCF-1 maintaining CD8+ T cell stemness and TOX promoting T cell exhaustion. The prognostic significance of these factors in lung adenocarcinoma (LUAD) remains a critical area of investigation. The retrospective study included 191 patients with LUAD who underwent surgery, of whom 83% were in stages II and III. These patients were divided into exploratory (n = 135) and validation (n = 56) groups based on the time of diagnosis. Multiplex fluorescence immunohistochemistry was used to examine the infiltration levels of CD8+ T cells, TCF1+ CD8+ T cells, and TOX+ CD8+ T cells. The percentage of CD8+ T cells in tumor was markedly lower than that in stroma (p < 0.05). In tumor-draining lymph nodes (TDLNs) invaded by tumor, the proportion of stem-like TCF1+ CD8+ T cells was significantly decreased (p < 0.01). Importantly, higher infiltration levels of CD8+ T cells and TCF1+ CD8+ T cells were associated with improved disease-free survival (DFS) (p = 0.009 and p = 0.006, respectively) and overall survival (OS) (p = 0.018 and p = 0.010, respectively). This study underscores the potential of TCF1+ CD8+ T cells as prognostic biomarkers in LUAD, providing insights into the tumor immune microenvironment and guiding future therapeutic strategies.
(© 2024 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.)
References: Trends Immunol. 2019 Dec;40(12):1149-1162. (PMID: 31734149)
Cancer Sci. 2024 Jul;115(7):2184-2195. (PMID: 38590234)
Thorac Cancer. 2023 Sep;14(27):2745-2753. (PMID: 37536668)
Nature. 2018 Jan 24;553(7689):446-454. (PMID: 29364287)
Nature. 2014 Nov 27;515(7528):568-71. (PMID: 25428505)
Immunity. 2016 Aug 16;45(2):415-27. (PMID: 27533016)
J Natl Compr Canc Netw. 2022 May;20(5):497-530. (PMID: 35545176)
JTO Clin Res Rep. 2021 Nov 25;3(1):100257. (PMID: 34977823)
Cell. 2022 Oct 27;185(22):4049-4066.e25. (PMID: 36208623)
Cancer Commun (Lond). 2019 Apr 29;39(1):22. (PMID: 31030667)
Trends Immunol. 2012 Jun;33(6):271-80. (PMID: 22459312)
PLoS One. 2014 Sep 19;9(9):e106914. (PMID: 25238252)
Nature. 2018 May;557(7706):575-579. (PMID: 29769722)
Nature. 2019 Jul;571(7764):270-274. (PMID: 31207604)
Nat Immunol. 2009 Jan;10(1):29-37. (PMID: 19043418)
J Exp Med. 2022 Jun 6;219(6):. (PMID: 35472220)
Cancer Med. 2020 Sep;9(18):6694-6709. (PMID: 32700817)
Sci Immunol. 2021 Sep 10;6(63):eabg3551. (PMID: 34516744)
Annu Rev Immunol. 2019 Apr 26;37:457-495. (PMID: 30676822)
Sci Immunol. 2021 Oct;6(64):eabg7836. (PMID: 34597124)
EBioMedicine. 2022 Oct;84:104265. (PMID: 36116212)
Nat Immunol. 2019 Mar;20(3):326-336. (PMID: 30778252)
Nat Rev Clin Oncol. 2020 Jun;17(6):341-348. (PMID: 32112054)
Genome Med. 2020 Feb 28;12(1):22. (PMID: 32111241)
Front Immunol. 2022 Feb 22;13:806877. (PMID: 35273597)
Cancer Lett. 2021 Feb 28;499:137-147. (PMID: 33249194)
Cell Mol Immunol. 2021 May;18(5):1262-1277. (PMID: 32341523)
Cancer Cell. 2023 Sep 11;41(9):1662-1679.e7. (PMID: 37625402)
Immunity. 2019 Jan 15;50(1):195-211.e10. (PMID: 30635237)
Nat Commun. 2022 Aug 18;13(1):4851. (PMID: 35982052)
Clin Cancer Res. 2008 Aug 15;14(16):5220-7. (PMID: 18698040)
BMC Med Res Methodol. 2017 Apr 7;17(1):53. (PMID: 28388943)
J Transl Med. 2022 May 23;20(1):241. (PMID: 35606862)
Nature. 2019 Dec;576(7787):465-470. (PMID: 31827286)
Science. 2018 Mar 23;359(6382):1403-1407. (PMID: 29567713)
Nat Med. 2018 Jul;24(7):994-1004. (PMID: 29892065)
Nat Rev Cancer. 2012 Mar 15;12(4):298-306. (PMID: 22419253)
Nature. 2019 Jul;571(7764):211-218. (PMID: 31207603)
Cells. 2021 Mar 12;10(3):. (PMID: 33808959)
Immunity. 2020 May 19;52(5):825-841.e8. (PMID: 32396847)
Nature. 2015 Jul 30;523(7562):612-6. (PMID: 26123020)
Immunity. 2023 Jan 10;56(1):107-124.e5. (PMID: 36580918)
Nature. 2016 Sep 15;537(7620):417-421. (PMID: 27501248)
Immunity. 2021 Oct 12;54(10):2338-2353.e6. (PMID: 34534439)
Nat Rev Immunol. 2019 Nov;19(11):665-674. (PMID: 31570879)
Nat Rev Cancer. 2012 Mar 22;12(4):252-64. (PMID: 22437870)
Cancer Cell. 2023 Apr 10;41(4):776-790.e7. (PMID: 37001526)
Sci Immunol. 2016 Dec 23;1(6):. (PMID: 28018990)
Cancer Sci. 2021 Dec;112(12):4968-4976. (PMID: 34657342)
Science. 2015 Apr 3;348(6230):56-61. (PMID: 25838373)
Sci Immunol. 2020 Jul 3;5(49):. (PMID: 32620560)
معلومات مُعتمدة: 81972796 National Natural Science Foundation of China; 82272845 National Natural Science Foundation of China; flzh202107 Beijing Bethune Charitable Foundation; 2021SFGC0501 the Key Research and Development Program of Shandong; ZR2023LZL001 the Natural Science Foundation of Shandong Province
فهرسة مساهمة: Keywords: LUAD; TCF1; prognosis; tumor microenvironment; tumor‐draining lymph nodes
المشرفين على المادة: 0 (Hepatocyte Nuclear Factor 1-alpha)
0 (TOX protein, human)
0 (HNF1A protein, human)
0 (High Mobility Group Proteins)
0 (Trans-Activators)
تواريخ الأحداث: Date Created: 20240409 Date Completed: 20240712 Latest Revision: 20240717
رمز التحديث: 20240717
مُعرف محوري في PubMed: PMC11247562
DOI: 10.1111/cas.16177
PMID: 38590234
قاعدة البيانات: MEDLINE
الوصف
تدمد:1349-7006
DOI:10.1111/cas.16177